alexa Prognostic significance of young age (<35 years) by subtype based on ER, PR, and HER2 status in breast cancer: a nationwide registry-based study.


Journal of Cancer Science & Therapy

Author(s): Kim EK, Noh WC, Han W, Noh DY

Abstract Share this page

Abstract BACKGROUND: Young age is regarded as an adverse prognostic factor in patients with breast cancer, especially in those with a hormone receptor (HR)-positive tumor. We investigated the prognostic significance of an age of <35 years stratified by molecular subtype based on HR and HER2. METHODS: Two large databases of Korean breast cancer patients, which included nationwide registry data, were analyzed. RESULTS: In an analysis of 2,474 patients from the single institution, an age of <35 years was found to be an independent predictor of recurrence in patients with HR+/HER2- (hazard ratio 1.87; 95\% confidence interval [CI]: 1.11-3.14; P=0.018), HR+/HER2+ (hazard ratio 3.09; 95\% CI: 1.19-8.03; P=0.020), and HR-/HER2+ (hazard ratio 2.01; 95\% CI: 1.03-3.92; P=0.040) subtypes, but not in those with the HR-/HER2- (triple-negative, TN) subtype (hazard ratio 1.08; 95\% CI: 0.60-1.95; P=0.802). The results of an analysis of nationwide database data on 31,672 patients also showed that an age of <35 years significantly predicted poor cancer-specific survival in patients with HR+/HER2- (hazard ratio 3.40; 95\% CI: 2.41-4.82; P<0.001), HR+/HER2+ (hazard ratio 1.96; 95\% CI: 1.23-3.12; P=0.005), and HR-/HER2+ (hazard ratio 1.65; 95\% CI: 1.07-2.52; P=0.022) subtypes, but again not in those with the TN subtype (hazard ratio 1.21; 95\% CI: 0.88-1.67; P=0.240). CONCLUSION: The prognostic significance of young age was found to depend on molecular subtype. An age of <35 years was a poor prognosticator in patients with the HR+/HER2-, HR+/HER2+, and HR-/HER2+ subtypes, but not in those with the TN subtype. This article was published in World J Surg and referenced in Journal of Cancer Science & Therapy

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

1-702-714-7001Extn: 9037

Business & Management Journals


1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

1-702-714-7001 Extn: 9042

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version